Cantor analyst Elemer Piros raised his price target for GW Pharmaceuticals to $208 from $182 following its Epidiolex data presented at the American Epilepsy Society meeting. The analyst believes the data illustrates "robustness and remarkable consistency" across two distinct forms of epilepsy, Lennox Gastaut and Dravet syndrome and notes that the company laid to rest the largely overblown concern regarding drug interaction with clobazam. Piros believes GW Pharmaceuticals is in "good shape" for a New Drug Application covering both indications by the end of 1H17, and reiterates a Buy rating on the shares.